Upper Respiratory Tract Infection Treatment Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, China, Japan, Germany, UK - Size and Forecast 2024-2028

Published: Oct 2023 Pages: 170 SKU: IRTNTR43396

Upper Respiratory Tract Infection Treatment Market 2024-2028

The global upper respiratory tract infection treatment market size is estimated to grow by USD 2,661.15 million at a CAGR of 4.21% between 2023 and 2028. 

Top players in the market would be encouraged to concentrate on developing drugs that treat upper tract infections given the high prevalence of these infections. In the pipeline, a number of late-stage molecules are likely to be launched over the next few years. For instance, Emergo Therapeutics is developing norketotifen, an antagonist of the histamine H1 receptor and mast stabilizer, to treat allergic rhinitis. The drug is currently in a Phase II clinical trial. Hence, such a favorable drug pipeline will boost the growth of the market growth during the forecast period.

Technavio has segmented the market into Type, Distribution Channel, and Application

  • The type segment includes antibiotics, NSAIDs and nasal decongestants, and others
  • The distribution channel segment includes hospital pharmacies, retail pharmacies, and online pharmacies
  • The geography segment includes key regions such as North America, Europe, Asia, and Rest of World (ROW)

It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historic data from 2018 to 2022, besides analyzing the current market scenario.

What will be the Size of the Upper Respiratory Tract Infection Treatment Market During the Forecast Period?

To learn more about this report, Request Free Sample

Upper Respiratory Tract Infection Treatment Market Segmentation by Type, Distribution Channel, and Application Analysis

Type Analysis 

Antibiotics

The market share growth by the antibiotics segment will be significant during the forecast period. This segment contains antibiotics such as azithromycin, amoxicillin, doxycycline, clarithromycin, erythromycin, and VIBRAMYCIN. The comfortable availability of antibiotics to treat upper respiratory tract infections and their signs will drive the market growth. Upper respiratory tract infections are caused by bacteria such as Streptococcus pneumoniae, Chlamydia pneumonia.

Get a glance at the market contribution of various segments View a PDF Sample

The antibiotics segment was valued at USD 5,818.83 million in 2018. Antibiotics are used to treat various symptoms, such as pneumonia, influenza, and other respiratory tract infections. Furthermore, the widespread prevalence of respiratory tract infections across the globe, the increasing resistance of bacteria to non-antibiotic treatments, and the growing awareness among healthcare professionals about appropriate antibiotic usage and the development of new and more potent antibiotics will drive the growth of the antibiotics segment of the market during the forecast period.

Distribution Channel Analysis

Hospital pharmacies

Hospital pharmacies work closely with suppliers and pharmaceutical companies to purchase medications needed to treat the upper respiratory tract. These drugs are then stored in pharmaceutical warehouses. Inventory management systems help monitor stock levels and ensure that an adequate supply of respiratory medications is available. Moreover, hospital pharmacies often provide patient education on how to use respiratory medications correctly. This education contributes to better patient adherence and more effective drug distribution. These factors will contribute to the growth of the hospital pharmacies segment, which will drive the growth of the market in focus during the forecast period.

Retail pharmacies

The market has a well-established offline distribution channel that includes various types of retail pharmacy stores, such as drugstores, supermarkets, hypermarkets, and convenience stores. The primary mode of distribution of onychomycosis drugs is through these retail pharmacies, which have a wide geographical presence and are easily accessible to consumers. Moreover, the increasing number of pharmacy stores, supermarkets, and hypermarkets, the ease of availability of OTC/antibiotics drugs across platforms, and the easy accessibility to outlets are estimated to drive the growth of the retail pharmacies segment of the global upper respiratory tract infection treatment market during the forecast period

Regional Analysis

For more insights about the market share of various regions View PDF Sample now!

North America is estimated to contribute 47% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. The North American market is dominated by the US and is driven by increasing rates of upper respiratory tract infection therapeutic. The growing elderly population requires more respiratory drugs and medical services. North America, especially the US and Canada, has an aging population, increasing the incidence of respiratory diseases.

Furthermore, the presence of specialized respiratory care centers and clinics across North America ensures comprehensive care for patients with respiratory conditions, driving demand for respiratory medications. Thus, these factors will propel the upper respiratory tract infection treatment market in the region during the forecast period.

COVID Recovery Analysis

The outbreak of COVID-19 affected all countries in North America, especially the US and Canada, which negatively affected the upper respiratory tract infection therapeutic market in the region in 2020. However, in 2021, the initiation of large-scale vaccination drives?lifted the lockdown and travel restrictions, which led to the resumption of business activities. In addition to that, the COVID-19 pandemic has heightened awareness of respiratory health, potentially leading to increased attention on respiratory care, research, and management. Thus, this is expected to boost the growth of the upper respiratory tract infection treatment market in North America during the forecast period.

Buy Now Full Report and Discover More

Key Upper Respiratory Tract Infection Treatment Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 14 market companies, including:

AstraZeneca Plc: The company offers upper respiratory tract and immunolofy treatment that care for patients, moving beyond symptom control to disease modification, remission and, one day cure.

  • CSL Ltd.
  • GlaxoSmithKline Plc
  • MD Total Care LLC.
  • Medtronic Plc
  • Merck and Co. Inc.
  • Novartis AG
  • Parkway Holdings Ltd.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • The Cleveland Clinic Foundation
  • Yashoda Hospitals

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Upper Respiratory Tract Infection Treatment Market: Key Drivers, Trends, Challenges, and Customer Landscape

There are multiple factors influencing market growth. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. 

Key Upper Respiratory Tract Infection Treatment Market Drivers

Rising demand for over-the-counter drugs is the key factor driving market growth. Patients with colds and coughs often avoid seeing a healthcare professional because the infection can be self-treated with over-the-counter medications. Nasal decongestants such as Afrin (oxymetazoline nasal), Neo-Synephrine (phenylephrine nasal), and Sudafed PE (phenylephrine oral) are some of the over-the-counter drugs that help unclog congested nose.

Moreover, in the case of allergic rhinitis, over-the-counter pills such as Claritin, Alavert, Astelin, and Astepro do not require a written prescription from a healthcare professional and can be directly purchased from a pharmacy. Thus, rising demand for OTC drugs will have a positive impact on the growth of the global upper respiratory tract infection treatment market during the forecast period.

Significant Upper Respiratory Tract Infection Treatment Market Trends

The development of drug-delivery devices to treat upper respiratory tract infections is a primary trend shaping market growth. The development of drug-delivery devices to treat upper respiratory tract infection therapeutic will accelerate market growth. For example, Intersect ENT Inc. (Intersect ENT) is developing a novel device known as ASCEND, an investigational drug-coated sinus balloon. It is designed to deliver corticosteroids directly into sinuses at the time of dilation.

Likewise, Intersect ENTs PROPEL products are the first and only dissolvable implants designed to release mometasone furoate and are approved by the US FDA. PROPEL Contour is indicated for the frontal and maxillary sinuses and PROPEL Mini is indicated for the ethmoid and frontal sinuses. ThusThereforethe development of drug-delivery devices to treat upper respiratory tract infections will propel the growth of the market during the forecast period.

Major Upper Respiratory Tract Infection Treatment Market Challenges

Side effects of NSAIDs is a challenge that affects market growth. NSAIDs are used to treat upper respiratory tract infections therapeutically. However, these drugs are associated with side effects, which can pose a challenge to the market. NSAIDs such as aspirin, ibuprofen, and naproxen are used to treat the common cold. Common side effects of ibuprofen include stomach upset, mild heartburn, nausea, vomiting, bloating, gas, diarrhea, and constipation.

In addition, NSAIDs can cause an increased risk of adverse gastrointestinal events, including bleeding, ulceration, and perforation of the stomach or intestines. Elderly patients with peptic ulcers are at a high risk of serious gastrointestinal events. Therefore, the side effects of NSAIDs have led to a decrease in patient compliance, which may impede market growth during the forecast period.

Buy Now Full Report and Discover More

Key Upper Respiratory Tract Infection Treatment Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Upper Respiratory Tract Infection Treatment Market Customer Landscape

Segment Overview

The upper respiratory tract infection treatment market report forecasts market growth by revenue at global, regional & country levels and analyzes the latest trends and growth opportunities from 2018 to 2028. 

  • Type Outlook (USD Million, 2018 - 2028)
    • Antibiotics
    • NSAIDs and nasal decongestants
    • Others
  • Distribution Channel Outlook (USD Million, 2018 - 2028)
    • Hospital pharmacies
    • Retail pharmacies
    • Online pharmacies
  • Region Outlook (USD Million, 2018 - 2028)
    • North America
      • The U.S.
      • Canada
    • Europe
      • The U.K.
      • Germany
      • France
      • Rest of Europe
    • Asia
      • China
      • India
    • Rest of World (ROW)
      • Australia
      • Brazil
      • Argentina

Upper Respiratory Tract Infection Treatment Market Scope

Report Coverage

Details

Page number

170

Base year

2023

Historic period

2018-2022

Forecast period

2024-2028

Growth momentum & CAGR

Accelerate at a CAGR of 4.21%

Market growth 2024-2028

USD 2,661.15 million

Market structure

Concentrated

YoY growth 2023-2024(%)

3.46

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 47%

Key countries

US, Canada, Germany, UK, and China

Competitive landscape

 Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks

Key companies profiled

AstraZeneca Plc, CSL Ltd., GlaxoSmithKline Plc, MD Total Care LLC., Medtronic Plc, Merck and Co. Inc., Novartis AG, Parkway Holdings Ltd., Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi, Teva Pharmaceutical Industries Ltd., The Cleveland Clinic Foundation, and Yashoda Hospitals

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

View Sample PDF at your Fingertips

What are the Key Data Covered in this Upper Respiratory Tract Infection Treatment Market Research Report?

  • CAGR of the market during the forecast period
  • Detailed information on factors that will drive the growth of the upper respiratory tract infection treatment market between 2024 and 2028
  • Precise estimation of the upper respiratory tract infection treatment market size and its contribution to the market in focus on the parent market
  • Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria 
  • Companies landscape comparing criticality of inputs and factors of differentiation
  • Exclusive Matrix on companies' position and classification
  • Accurate predictions about upcoming trends and changes in consumer behavior
  • Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
  • A thorough analysis of the market’s competitive landscape and detailed information about companies
  • Comprehensive analysis of factors that will challenge the growth of upper respiratory tract infection treatment market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Type
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by Distribution Channel
    • Exhibit 07: Executive Summary – Chart on Incremental Growth
    • Exhibit 08: Executive Summary – Data Table on Incremental Growth
    • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 10: Parent market
    • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 13: Market segments
  • 3.3 Market size 2023
    • 3.4 Market outlook: Forecast for 2023-2028
      • Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
      • Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
      • Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
      • Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

    4 Historic Market Size

    • 4.1 Global upper respiratory tract infection treatment market 2018 - 2022
      • Exhibit 18: Historic Market Size – Data Table on global upper respiratory tract infection treatment market 2018 - 2022 ($ million)
    • 4.2 Type Segment Analysis 2018 - 2022
      • Exhibit 19: Historic Market Size – Type Segment 2018 - 2022 ($ million)
    • 4.3 Distribution Channel Segment Analysis 2018 - 2022
      • Exhibit 20: Historic Market Size – Distribution Channel Segment 2018 - 2022 ($ million)
    • 4.4 Geography Segment Analysis 2018 - 2022
      • Exhibit 21: Historic Market Size – Geography Segment 2018 - 2022 ($ million)
    • 4.5 Country Segment Analysis 2018 - 2022
      • Exhibit 22: Historic Market Size – Country Segment 2018 - 2022 ($ million)

    5 Five Forces Analysis

    • 5.1 Five forces summary
      • Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
    • 5.2 Bargaining power of buyers
      • Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028
    • 5.3 Bargaining power of suppliers
      • Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2023 and 2028
    • 5.4 Threat of new entrants
      • Exhibit 26: Threat of new entrants – Impact of key factors in 2023 and 2028
    • 5.5 Threat of substitutes
      • Exhibit 27: Threat of substitutes – Impact of key factors in 2023 and 2028
    • 5.6 Threat of rivalry
      • Exhibit 28: Threat of rivalry – Impact of key factors in 2023 and 2028
    • 5.7 Market condition
      • Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

    6 Market Segmentation by Type

    • 6.1 Market segments
      • Exhibit 30: Chart on Type - Market share 2023-2028 (%)
      • Exhibit 31: Data Table on Type - Market share 2023-2028 (%)
    • 6.2 Comparison by Type
      • Exhibit 32: Chart on Comparison by Type
      • Exhibit 33: Data Table on Comparison by Type
    • 6.3 Antibiotics - Market size and forecast 2023-2028
      • Exhibit 34: Chart on Antibiotics - Market size and forecast 2023-2028 ($ million)
      • Exhibit 35: Data Table on Antibiotics - Market size and forecast 2023-2028 ($ million)
      • Exhibit 36: Chart on Antibiotics - Year-over-year growth 2023-2028 (%)
      • Exhibit 37: Data Table on Antibiotics - Year-over-year growth 2023-2028 (%)
    • 6.4 NSAIDs and nasal decongestants - Market size and forecast 2023-2028
      • Exhibit 38: Chart on NSAIDs and nasal decongestants - Market size and forecast 2023-2028 ($ million)
      • Exhibit 39: Data Table on NSAIDs and nasal decongestants - Market size and forecast 2023-2028 ($ million)
      • Exhibit 40: Chart on NSAIDs and nasal decongestants - Year-over-year growth 2023-2028 (%)
      • Exhibit 41: Data Table on NSAIDs and nasal decongestants - Year-over-year growth 2023-2028 (%)
    • 6.5 Others - Market size and forecast 2023-2028
      • Exhibit 42: Chart on Others - Market size and forecast 2023-2028 ($ million)
      • Exhibit 43: Data Table on Others - Market size and forecast 2023-2028 ($ million)
      • Exhibit 44: Chart on Others - Year-over-year growth 2023-2028 (%)
      • Exhibit 45: Data Table on Others - Year-over-year growth 2023-2028 (%)
    • 6.6 Market opportunity by Type
      • Exhibit 46: Market opportunity by Type ($ million)
      • Exhibit 47: Data Table on Market opportunity by Type ($ million)

    7 Market Segmentation by Distribution Channel

    • 7.1 Market segments
      • Exhibit 48: Chart on Distribution Channel - Market share 2023-2028 (%)
      • Exhibit 49: Data Table on Distribution Channel - Market share 2023-2028 (%)
    • 7.2 Comparison by Distribution Channel
      • Exhibit 50: Chart on Comparison by Distribution Channel
      • Exhibit 51: Data Table on Comparison by Distribution Channel
    • 7.3 Hospital pharmacies - Market size and forecast 2023-2028
      • Exhibit 52: Chart on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
      • Exhibit 53: Data Table on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
      • Exhibit 54: Chart on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
      • Exhibit 55: Data Table on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
    • 7.4 Retail pharmacies - Market size and forecast 2023-2028
      • Exhibit 56: Chart on Retail pharmacies - Market size and forecast 2023-2028 ($ million)
      • Exhibit 57: Data Table on Retail pharmacies - Market size and forecast 2023-2028 ($ million)
      • Exhibit 58: Chart on Retail pharmacies - Year-over-year growth 2023-2028 (%)
      • Exhibit 59: Data Table on Retail pharmacies - Year-over-year growth 2023-2028 (%)
    • 7.5 Online pharmacies - Market size and forecast 2023-2028
      • Exhibit 60: Chart on Online pharmacies - Market size and forecast 2023-2028 ($ million)
      • Exhibit 61: Data Table on Online pharmacies - Market size and forecast 2023-2028 ($ million)
      • Exhibit 62: Chart on Online pharmacies - Year-over-year growth 2023-2028 (%)
      • Exhibit 63: Data Table on Online pharmacies - Year-over-year growth 2023-2028 (%)
    • 7.6 Market opportunity by Distribution Channel
      • Exhibit 64: Market opportunity by Distribution Channel ($ million)
      • Exhibit 65: Data Table on Market opportunity by Distribution Channel ($ million)

    8 Customer Landscape

    • 8.1 Customer landscape overview
      • Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    9 Geographic Landscape

    • 9.1 Geographic segmentation
      • Exhibit 67: Chart on Market share by geography 2023-2028 (%)
      • Exhibit 68: Data Table on Market share by geography 2023-2028 (%)
    • 9.2 Geographic comparison
      • Exhibit 69: Chart on Geographic comparison
      • Exhibit 70: Data Table on Geographic comparison
    • 9.3 North America - Market size and forecast 2023-2028
      • Exhibit 71: Chart on North America - Market size and forecast 2023-2028 ($ million)
      • Exhibit 72: Data Table on North America - Market size and forecast 2023-2028 ($ million)
      • Exhibit 73: Chart on North America - Year-over-year growth 2023-2028 (%)
      • Exhibit 74: Data Table on North America - Year-over-year growth 2023-2028 (%)
    • 9.4 Europe - Market size and forecast 2023-2028
      • Exhibit 75: Chart on Europe - Market size and forecast 2023-2028 ($ million)
      • Exhibit 76: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
      • Exhibit 77: Chart on Europe - Year-over-year growth 2023-2028 (%)
      • Exhibit 78: Data Table on Europe - Year-over-year growth 2023-2028 (%)
    • 9.5 Asia - Market size and forecast 2023-2028
      • Exhibit 79: Chart on Asia - Market size and forecast 2023-2028 ($ million)
      • Exhibit 80: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
      • Exhibit 81: Chart on Asia - Year-over-year growth 2023-2028 (%)
      • Exhibit 82: Data Table on Asia - Year-over-year growth 2023-2028 (%)
    • 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
      • Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
      • Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
      • Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
      • Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
    • 9.7 US - Market size and forecast 2023-2028
      • Exhibit 87: Chart on US - Market size and forecast 2023-2028 ($ million)
      • Exhibit 88: Data Table on US - Market size and forecast 2023-2028 ($ million)
      • Exhibit 89: Chart on US - Year-over-year growth 2023-2028 (%)
      • Exhibit 90: Data Table on US - Year-over-year growth 2023-2028 (%)
    • 9.8 Canada - Market size and forecast 2023-2028
      • Exhibit 91: Chart on Canada - Market size and forecast 2023-2028 ($ million)
      • Exhibit 92: Data Table on Canada - Market size and forecast 2023-2028 ($ million)
      • Exhibit 93: Chart on Canada - Year-over-year growth 2023-2028 (%)
      • Exhibit 94: Data Table on Canada - Year-over-year growth 2023-2028 (%)
    • 9.9 Germany - Market size and forecast 2023-2028
      • Exhibit 95: Chart on Germany - Market size and forecast 2023-2028 ($ million)
      • Exhibit 96: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
      • Exhibit 97: Chart on Germany - Year-over-year growth 2023-2028 (%)
      • Exhibit 98: Data Table on Germany - Year-over-year growth 2023-2028 (%)
    • 9.10 UK - Market size and forecast 2023-2028
      • Exhibit 99: Chart on UK - Market size and forecast 2023-2028 ($ million)
      • Exhibit 100: Data Table on UK - Market size and forecast 2023-2028 ($ million)
      • Exhibit 101: Chart on UK - Year-over-year growth 2023-2028 (%)
      • Exhibit 102: Data Table on UK - Year-over-year growth 2023-2028 (%)
    • 9.11 China - Market size and forecast 2023-2028
      • Exhibit 103: Chart on China - Market size and forecast 2023-2028 ($ million)
      • Exhibit 104: Data Table on China - Market size and forecast 2023-2028 ($ million)
      • Exhibit 105: Chart on China - Year-over-year growth 2023-2028 (%)
      • Exhibit 106: Data Table on China - Year-over-year growth 2023-2028 (%)
    • 9.12 Market opportunity by geography
      • Exhibit 107: Market opportunity by geography ($ million)
      • Exhibit 108: Data Tables on Market opportunity by geography ($ million)

    10 Drivers, Challenges, and Trends

    • 10.1 Market drivers
      • 10.2 Market challenges
        • 10.3 Impact of drivers and challenges
          • Exhibit 109: Impact of drivers and challenges in 2023 and 2028
        • 10.4 Market trends

          11 Vendor Landscape

          • 11.1 Overview
            • 11.2 Vendor landscape
              • Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
            • 11.3 Landscape disruption
              • Exhibit 111: Overview on factors of disruption
            • 11.4 Industry risks
              • Exhibit 112: Impact of key risks on business

            12 Vendor Analysis

            • 12.1 Vendors covered
              • Exhibit 113: Vendors covered
            • 12.2 Market positioning of vendors
              • Exhibit 114: Matrix on vendor position and classification
            • 12.3 AstraZeneca Plc
              • Exhibit 115: AstraZeneca Plc - Overview
              • Exhibit 116: AstraZeneca Plc - Product / Service
              • Exhibit 117: AstraZeneca Plc - Key news
              • Exhibit 118: AstraZeneca Plc - Key offerings
            • 12.4 CSL Ltd.
              • Exhibit 119: CSL Ltd. - Overview
              • Exhibit 120: CSL Ltd. - Business segments
              • Exhibit 121: CSL Ltd. - Key offerings
              • Exhibit 122: CSL Ltd. - Segment focus
            • 12.5 GlaxoSmithKline Plc
              • Exhibit 123: GlaxoSmithKline Plc - Overview
              • Exhibit 124: GlaxoSmithKline Plc - Business segments
              • Exhibit 125: GlaxoSmithKline Plc - Key news
              • Exhibit 126: GlaxoSmithKline Plc - Key offerings
              • Exhibit 127: GlaxoSmithKline Plc - Segment focus
            • 12.6 MD Total Care LLC.
              • Exhibit 128: MD Total Care LLC. - Overview
              • Exhibit 129: MD Total Care LLC. - Product / Service
              • Exhibit 130: MD Total Care LLC. - Key offerings
            • 12.7 Medtronic Plc
              • Exhibit 131: Medtronic Plc - Overview
              • Exhibit 132: Medtronic Plc - Business segments
              • Exhibit 133: Medtronic Plc - Key news
              • Exhibit 134: Medtronic Plc - Key offerings
              • Exhibit 135: Medtronic Plc - Segment focus
            • 12.8 Merck and Co. Inc.
              • Exhibit 136: Merck and Co. Inc. - Overview
              • Exhibit 137: Merck and Co. Inc. - Business segments
              • Exhibit 138: Merck and Co. Inc. - Key news
              • Exhibit 139: Merck and Co. Inc. - Key offerings
              • Exhibit 140: Merck and Co. Inc. - Segment focus
            • 12.9 Novartis AG
              • Exhibit 141: Novartis AG - Overview
              • Exhibit 142: Novartis AG - Business segments
              • Exhibit 143: Novartis AG - Key offerings
              • Exhibit 144: Novartis AG - Segment focus
            • 12.10 Parkway Holdings Ltd.
              • Exhibit 145: Parkway Holdings Ltd. - Overview
              • Exhibit 146: Parkway Holdings Ltd. - Product / Service
              • Exhibit 147: Parkway Holdings Ltd. - Key offerings
            • 12.11 Pfizer Inc.
              • Exhibit 148: Pfizer Inc. - Overview
              • Exhibit 149: Pfizer Inc. - Product / Service
              • Exhibit 150: Pfizer Inc. - Key news
              • Exhibit 151: Pfizer Inc. - Key offerings
            • 12.12 Regeneron Pharmaceuticals Inc.
              • Exhibit 152: Regeneron Pharmaceuticals Inc. - Overview
              • Exhibit 153: Regeneron Pharmaceuticals Inc. - Product / Service
              • Exhibit 154: Regeneron Pharmaceuticals Inc. - Key offerings
            • 12.13 Sanofi
              • Exhibit 155: Sanofi - Overview
              • Exhibit 156: Sanofi - Business segments
              • Exhibit 157: Sanofi - Key news
              • Exhibit 158: Sanofi - Key offerings
              • Exhibit 159: Sanofi - Segment focus
            • 12.14 Teva Pharmaceutical Industries Ltd.
              • Exhibit 160: Teva Pharmaceutical Industries Ltd. - Overview
              • Exhibit 161: Teva Pharmaceutical Industries Ltd. - Business segments
              • Exhibit 162: Teva Pharmaceutical Industries Ltd. - Key news
              • Exhibit 163: Teva Pharmaceutical Industries Ltd. - Key offerings
              • Exhibit 164: Teva Pharmaceutical Industries Ltd. - Segment focus
            • 12.15 The Cleveland Clinic Foundation
              • Exhibit 165: The Cleveland Clinic Foundation - Overview
              • Exhibit 166: The Cleveland Clinic Foundation - Product / Service
              • Exhibit 167: The Cleveland Clinic Foundation - Key offerings
            • 12.16 Yashoda Hospitals
              • Exhibit 168: Yashoda Hospitals - Overview
              • Exhibit 169: Yashoda Hospitals - Product / Service
              • Exhibit 170: Yashoda Hospitals - Key offerings

            13 Appendix

            • 13.1 Scope of the report
              • 13.2 Inclusions and exclusions checklist
                • Exhibit 171: Inclusions checklist
                • Exhibit 172: Exclusions checklist
              • 13.3 Currency conversion rates for US$
                • Exhibit 173: Currency conversion rates for US$
              • 13.4 Research methodology
                • Exhibit 174: Research methodology
                • Exhibit 175: Validation techniques employed for market sizing
                • Exhibit 176: Information sources
              • 13.5 List of abbreviations
                • Exhibit 177: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              INFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases

              DATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts

              REPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape

              PURCHASE FULL REPORT OF

              upper respiratory tract infection treatment market

              QUICK BUY

              Key Questions Answered

              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?

              Why should you prefer Technavio's market insights report?

              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis